Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T C Chan

Showing results (381-390 of 407) with videos related to

Pageof 41
Sort By:
International Journal of Radiation Oncology, Biology, Physics|August 15, 2006
Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinomaAnne W M Lee, Stewart Y Tung, Anthony T C Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO GuidelineYu-Pei Chen, Nofisat Ismaila, Melvin L K Chua, et al.
The Lancet. Oncology|May 11, 2015
Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysisPierre Blanchard, Anne Lee, Sophie Marguet, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 22, 2006
Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG)Peter M L Teo, Sing Fai Leung, Stewart Y Tung, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencingK C Allen Chan, Peiyong Jiang, Carol W M Chan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 29, 2020
Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapyE P Hui, W F Li, B B Ma, et al.
The New England Journal of Medicine|August 10, 2017
Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal CancerK C Allen Chan, John K S Woo, Ann King, et al.
Journal of the National Cancer Institute|December 9, 2016
Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysisFederico Rotolo, Jean-Pierre Pignon, Jean Bourhis, et al.
Cancer Treatment Reviews|June 28, 2026
Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neckCarlo Resteghini, Athanassios Argiris, Pierre Blanchard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2012
Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research GroupWinnie Yeo, Hyun C Chung, Stephen L Chan, et al.
Pageof 41

Showing results (381-390 of 407) with videos related to

Sort By:
Pageof 41
International Journal of Radiation Oncology, Biology, Physics|August 15, 2006
Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinomaAnne W M Lee, Stewart Y Tung, Anthony T C Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO GuidelineYu-Pei Chen, Nofisat Ismaila, Melvin L K Chua, et al.
The Lancet. Oncology|May 11, 2015
Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysisPierre Blanchard, Anne Lee, Sophie Marguet, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 22, 2006
Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG)Peter M L Teo, Sing Fai Leung, Stewart Y Tung, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencingK C Allen Chan, Peiyong Jiang, Carol W M Chan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 29, 2020
Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapyE P Hui, W F Li, B B Ma, et al.
The New England Journal of Medicine|August 10, 2017
Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal CancerK C Allen Chan, John K S Woo, Ann King, et al.
Journal of the National Cancer Institute|December 9, 2016
Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysisFederico Rotolo, Jean-Pierre Pignon, Jean Bourhis, et al.
Cancer Treatment Reviews|June 28, 2026
Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neckCarlo Resteghini, Athanassios Argiris, Pierre Blanchard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2012
Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research GroupWinnie Yeo, Hyun C Chung, Stephen L Chan, et al.
Pageof 41